Kimberly Ann Hickman, LPN | |
2430 S Rockhill Ave, Alliance, OH 44601-5420 | |
(330) 312-0884 | |
Not Available |
Full Name | Kimberly Ann Hickman |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 2430 S Rockhill Ave, Alliance, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558069229 | NPI | - | NPPES |
103699 | Other | OH | LPN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 103699 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kimberly Ann Hickman, LPN 2430 S Rockhill Ave, Alliance, OH 44601-5420 Ph: (330) 312-0884 | Kimberly Ann Hickman, LPN 2430 S Rockhill Ave, Alliance, OH 44601-5420 Ph: (330) 312-0884 |
News Archive
It can be instructive to consider not just what long term care insurance professionals recommend, but what they do - for their own personal protection. A good example is the case of Kim Galatolo, an agent with LTC Financial Partners LLC one of the nation's most experienced long term care insurance agencies. In California, where Galatolo lives and works, the firm is known as LTC Partners & Insurance Services, LLC.
The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.
On January 4, 2018, a 13-year-old girl died and dozens of people were injured by carbon monoxide poisoning in Perth Amboy, NJ.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
› Verified 6 days ago